Photo credit: www.cbc.ca
A recent case involving a German HIV patient who achieved remission after a stem cell transplant has sparked renewed optimism about potential treatments for individuals living with both HIV and cancer. This groundbreaking case offers new insights into the possibilities of stem cell transplants as a means to combat the virus.
The process of stem cell transplantation for cancer treatment usually begins with the elimination of the patient’s immune cells through chemotherapy. For patients who are also HIV-positive, the next step involves replacing these destroyed cells with stem cells from donors who possess genetic traits conferring resistance to the virus. However, candidates for this type of transplant are exceedingly rare, as they must be simultaneously battling both HIV and cancer.
According to findings shared by Christian Gaebler from Charité — Berlin University’s medical school, the German patient received a stem cell transplant in 2015 while undergoing treatment for acute myeloid leukemia. Remarkably, this patient has been free from HIV treatment since 2018, with the virus remaining in remission. Notably, he is among only seven individuals documented to have gone into HIV remission globally between 2007 and 2023.
In most similar cases, transplant donors bore two copies of the CCR5 delta 32 gene, known for its ability to provide resistance against HIV. However, the German patient represents a unique instance in that his donor had inherited only one copy of this gene, a detail highlighted by Gaebler and his colleagues. This research has not yet undergone peer review.
During a virtual announcement at the 25th International AIDS Conference in Munich, Germany, researchers expressed hope that this case could facilitate broader access to such treatments for a greater number of people and yield significant implications for future HIV cure strategies.
“This case reinforces the notion that a cure is within reach, and that’s what these exceptional cases reveal,” emphasized Sharon Lewin, president of the International AIDS Society (IAS), while also acknowledging the rare nature of these occurrences.
Significance of the Case for Future Treatment Development
With the upcoming anniversary of the patient’s six-year remission approaching in September, researchers are growing more confident in their findings. “A healthy person has many wishes, a sick person only one,” the anonymous patient stated, highlighting the profound impact of his experience.
Dr. Marina Klein, a medicine professor at Montreal’s McGill University, noted that this case could shape the approach to developing new treatment methods. “This illustrates that complete resistance is not necessarily a requisite for achieving positive outcomes,” Klein remarked, even though she is not directly involved in the study.
Research indicates that approximately 1 percent of Caucasians possess two copies of the CCR5 gene, while around 20 percent have just one. Those with one copy of the gene experience a slower progression of the virus in the absence of antiretroviral therapy, compared to those with two copies, who can effectively suppress the virus.
Lewin further pointed out that the German patient’s situation implies potential expansion of the donor pool for similar cases, which may also lead to future advances in scalable HIV cure strategies.
Klein highlighted the challenges posed by the rise in HIV diagnoses, which surged nearly 25 percent between 2021 and 2022, complicating efforts to eradicate the disease. “Patients may become frustrated, yet these incremental advancements are crucial steps toward achieving a cure,” she stated.
Challenges Regarding Treatment Accessibility and Effectiveness
Professor Eric Arts from Western University emphasized the necessity of making successful treatment options widely available. Although he views the patient’s remission as promising, Arts noted the hurdles in applying this approach on a larger scale.
“The treatment designed primarily to address leukemia is not necessarily a feasible option for HIV,” he explained, emphasizing the need for universally available solutions to tackle the global HIV pandemic.
While antiretroviral therapies allow many individuals with HIV to lead normal lives, Arts argued that the risks and costs associated with stem cell transplants currently do not justify their use for those without alternative treatment options.
Jean-Paul Michael, an individual living with HIV, shared his journey in managing his condition with antiretroviral medications, despite initial barriers to accessing treatment. Michael emphasized the persistent stigma surrounding HIV, advocating for greater accessibility to medications.
The desire for a future where the immune system can effectively manage HIV without the need for continuous medication remains a shared aspiration among both Michael and Klein, indicating a collective push toward enhanced treatment avenues.
Source
www.cbc.ca